Phosphoproteomics of primary AML patient samples reveals rationale for AKT combination therapy and p53 context to overcome selinexor resistance

The TP53 Database: transition from the International Agency for Research on Cancer to the US National Cancer Institute

(2022) Kelvin César de Andrade et al.   CELL DEATH AND DIFFERENTIATION

BRD4-mediated repression of p53 is a target for combination therapy in AML

(2021) Anne-Louise Latif et al.   Nature Communications

Chemical Phosphoproteomics Sheds New Light on the Targets and Modes of Action of AKT Inhibitors

(2021) Svenja Wiechmann et al.   ACS Chemical Biology

Integrated intra‐ and intercellular signaling knowledge for multicellular omics analysis

(2021) Dénes Türei et al.   Molecular Systems Biology

Spatial-proteomics reveals phospho-signaling dynamics at subcellular resolution

(2021) Ana Martinez-Val et al.   Nature Communications

SciPy 1.0: fundamental algorithms for scientific computing in Python

(2020) Pauli Virtanen et al.   NATURE METHODS

Ex vivo cultures and drug testing of primary acute myeloid leukemia samples: Current techniques and implications for experimental design and outcome

(2020) D.G.J. Cucchi et al.   DRUG RESISTANCE UPDATES

Targeting FLT3 mutations in AML: review of current knowledge and evidence

(2019) Naval Daver et al.   LEUKEMIA

Protein aggregation capture on microparticles enables multi-purpose proteomics sample preparation.

(2019) Tanveer Singh Batth et al.   MOLECULAR & CELLULAR PROTEOMICS

Optimizing survival outcomes with post‐remission therapy in acute myeloid leukemia

(2019) Bruno C. Medeiros et al.   AMERICAN JOURNAL OF HEMATOLOGY

Selinexor in combination with decitabine in patients with acute myeloid leukemia: results from a phase 1 study

(2019) Bhavana Bhatnagar et al.   LEUKEMIA & LYMPHOMA

Dual Inhibition of MDM2 and XPO1 Synergizes to Induce Apoptosis in Acute Myeloid Leukemia Progenitor Cells with Wild-Type TP53 through Nuclear Accumulation of p53 and Suppression of c-Myc

(2019) Yuki Nishida et al.   BLOOD

Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia

(2019) Kendra Sweet et al.   CLINICAL CANCER RESEARCH

The functional landscape of the human phosphoproteome

(2019) David Ochoa et al.   NATURE BIOTECHNOLOGY

Dueling for dual inhibition: Means to enhance effectiveness of PI3K/Akt/mTOR inhibitors in AML

(2018) Lauren Herschbein et al.   BLOOD REVIEWS

A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia

(2018) Amy Y. Wang et al.   Journal of Hematology & Oncology

Benchmarking common quantification strategies for large-scale phosphoproteomics

(2018) Alexander Hogrebe et al.   Nature Communications

Anti-tumor efficacy of Selinexor (KPT-330) in gastric cancer is dependent on nuclear accumulation of p53 tumor suppressor

(2018) Vinod Vijay Subhash et al.   Scientific Reports

Clonal Heterogeneity Reflected by PI3K-AKT-mTOR Signaling in Human Acute Myeloid Leukemia Cells and Its Association with Adverse Prognosis

(2018) Ina Nepstad et al.   Cancers

Integrated proximal proteomics reveals IRS2 as a determinant of cell survival in ALK-driven neuroblastoma

(2018) Kristina B. Emdal et al.   Science Signaling

Optimization of Experimental Parameters in Data-Independent Mass Spectrometry Significantly Increases Depth and Reproducibility of Results

(2017) Roland Bruderer et al.   MOLECULAR & CELLULAR PROTEOMICS

The target landscape of clinical kinase drugs

(2017) Susan Klaeger et al.   SCIENCE

Phosphoproteomics of Primary Cells Reveals Druggable Kinase Signatures in Ovarian Cancer

(2017) Chiara Francavilla et al.   Cell Reports

DAPAR & ProStaR: software to perform statistical analyses in quantitative discovery proteomics

(2016) Samuel Wieczorek et al.   BIOINFORMATICS

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

(2016) Hartmut Döhner et al.   BLOOD

Quantitative Phosphoproteomics Reveals Wee1 Kinase as a Therapeutic Target in a Model of Proneural Glioblastoma

(2016) Rebecca S. Lescarbeau et al.   MOLECULAR CANCER THERAPEUTICS

The Perseus computational platform for comprehensive analysis of (prote)omics data

(2016) Stefka Tyanova et al.   NATURE METHODS

Genomic Classification and Prognosis in Acute Myeloid Leukemia

(2016) Elli Papaemmanuil et al.   NEW ENGLAND JOURNAL OF MEDICINE

eIF4B is a convergent target and critical effector of oncogenic Pim and PI3K/Akt/mTOR signaling pathways in Abl transformants

(2016) Ke Chen et al.   Oncotarget

limma powers differential expression analyses for RNA-sequencing and microarray studies

(2015) Matthew E. Ritchie et al.   NUCLEIC ACIDS RESEARCH

Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia

(2014) M. Y. Konopleva et al.   CLINICAL CANCER RESEARCH

PhosphoSitePlus, 2014: mutations, PTMs and recalibrations

(2014) Peter V. Hornbeck et al.   NUCLEIC ACIDS RESEARCH

Atomic basis of CRM1-cargo recognition, release and inhibition

(2014) Ho Yee Joyce Fung et al.   SEMINARS IN CANCER BIOLOGY

Prognostic impact and targeting of CRM1 in acute myeloid leukemia

(2013) K. Kojima et al.   BLOOD

KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia

(2013) Julia Etchin et al.   BRITISH JOURNAL OF HAEMATOLOGY

Enriching the gene set analysis of genome-wide data by incorporating directionality of gene expression and combining statistical hypotheses and methods

(2013) Leif Väremo et al.   NUCLEIC ACIDS RESEARCH

Kinase-Substrate Enrichment Analysis Provides Insights into the Heterogeneity of Signaling Pathway Activation in Leukemia Cells

(2013) P. Casado et al.   Science Signaling

CRM1 Inhibition Sensitizes Drug Resistant Human Myeloma Cells to Topoisomerase II and Proteasome Inhibitors both In Vitro and Ex Vivo

(2013) Joel G. Turner et al.   Journal of Cancer

Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia

(2012) P. Ranganathan et al.   BLOOD

An overview of the mTOR pathway as a target in cancer therapy

(2012) Ryan D Gentzler et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Identification of CRM1-dependent Nuclear Export Cargos Using Quantitative Mass Spectrometry

(2012) Ketan Thakar et al.   MOLECULAR & CELLULAR PROTEOMICS

InnateDB: systems biology of innate immunity and beyond—recent updates and continuing curation

(2012) Karin Breuer et al.   NUCLEIC ACIDS RESEARCH

mTORC1 Directly Phosphorylates and Regulates Human MAF1

(2010) A. A. Michels et al.   MOLECULAR AND CELLULAR BIOLOGY

MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo

(2010) H. Hirai et al.   MOLECULAR CANCER THERAPEUTICS

Pathway-Based Identification of Biomarkers for Targeted Therapeutics: Personalized Oncology with PI3K Pathway Inhibitors

(2010) J. N. Andersen et al.   Science Translational Medicine

The nuclear localization of 3'-phosphoinositide-dependent kinase-1 is dependent on its association with the protein tyrosine phosphatase SHP-1

(2009) C.F. Sephton et al.   CELLULAR SIGNALLING

Evaluation of in vivo antineoplastic effects of rapamycin in patients with chemotherapy-refractory AML

(2009) Alexandra Boehm et al.   European Journal of Internal Medicine

Improved visualization of protein consensus sequences by iceLogo

(2009) Niklaas Colaert et al.   NATURE METHODS

Lack of antileukemic activity of rapamycin in elderly patients with acute myeloid leukemia evolving from a myelodysplastic syndrome

(2008) Fernando Callera et al.   LEUKEMIA RESEARCH

MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification

(2008) Jürgen Cox et al.   NATURE BIOTECHNOLOGY